Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.

Pier Giorgio CojuttiManuela LuganoElda RighiGiorgio Della RoccaMatteo BassettiWilliam HopeFederico Pea

Published in: European journal of clinical pharmacology (2018)

Fluconazole dosages of 100-200 mg daily may ensure optimal PTA against C. albicans, C. parapsilosis, and C. tropicalis. Higher dosages are required against C. glabrata. Estimated creatinine clearance is not a reliable predictor of fluconazole clearance in LT patients.

Keyphrases

candida albicans
biofilm formation
end stage renal disease
ejection fraction
newly diagnosed
prognostic factors
physical activity
patient reported outcomes
staphylococcus aureus